NCT03085914 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 70
- units
- Participants
- groups
- description
- Epacadostat (Epa) oral twice-daily (BID) continuous daily dosing at the protocol-defined dose in combination with pembrolizumab administered intravenously (IV) in combination with mFOLFOX6 (oxaliplatin IV + leucovorin IV + 5-fluorouracil (5-FU) IV.
- id
- BG000
- title
- Group A: Epa + Pembrolizumab + mFOLFOX6
- description
- Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with nab-paclitaxel IV and gemcitabine IV.
- id
- BG001
- title
- Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine
- description
- Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) in combination with paclitaxel IV and carboplatin IV.
- id
- BG002
- title
- Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin
- description
- Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with pemetrexed IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.
- id
- BG003
- title
- Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent
- description
- Epa (100 mg)oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with cyclophosphamide PO.
- id
- BG004
- title
- Group E: Epa + Pembrolizumab + Cyclophosphamide
- description
- Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with gemcitabine IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.
- id
- BG005
- title
- Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
- description
- Epa (100 mg) oral BID continuousdaily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with 5-FU IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.
- id
- BG006
- title
- Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.03
- value
- 55.8
- group Id
- BG001
- spread
- 14.98
- value
- 46.0
- group Id
- BG002
- spread
- 12.11
- value
- 63.7
- group Id
- BG003
- spread
- 12.96
- value
- 58.2
- group Id
- BG004
- spread
- 10.21
- value
- 62.0
- group Id
- BG005
- spread
- 12.01
- value
- 60.3
- group Id
- BG006
- spread
- 12.24
- value
- 59.4
- group Id
- BG007
- spread
- 12.54
- value
- 58.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 10
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 36
- title
- Female
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 7
- group Id
- BG007
- value
- 34
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 10
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 55
- title
- White/Caucasian
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 6
- title
- Black/African-American
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Native Hawaiian/Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 5
- title
- Other
- title
- Race
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 67
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Not Reported
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Unknown
- title
- Ethnicity
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The safety population included all participants enrolled in the study who received at least 1 dose of epacadostat, pembrolizumab, or an applicable chemotherapy regimen.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 70
- units
- Participants
- groups
- description
- Epacadostat (Epa) oral twice-daily (BID) continuous daily dosing at the protocol-defined dose in combination with pembrolizumab administered intravenously (IV) in combination with mFOLFOX6 (oxaliplatin IV + leucovorin IV + 5-fluorouracil (5-FU) IV.
- id
- BG000
- title
- Group A: Epa + Pembrolizumab + mFOLFOX6
- description
- Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with nab-paclitaxel IV and gemcitabine IV.
- id
- BG001
- title
- Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine
- description
- Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) in combination with paclitaxel IV and carboplatin IV.
- id
- BG002
- title
- Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin
- description
- Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with pemetrexed IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.
- id
- BG003
- title
- Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent
- description
- Epa (100 mg)oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with cyclophosphamide PO.
- id
- BG004
- title
- Group E: Epa + Pembrolizumab + Cyclophosphamide
- description
- Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with gemcitabine IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.
- id
- BG005
- title
- Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
- description
- Epa (100 mg) oral BID continuousdaily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with 5-FU IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.
- id
- BG006
- title
- Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.03
- value
- 55.8
- group Id
- BG001
- spread
- 14.98
- value
- 46.0
- group Id
- BG002
- spread
- 12.11
- value
- 63.7
- group Id
- BG003
- spread
- 12.96
- value
- 58.2
- group Id
- BG004
- spread
- 10.21
- value
- 62.0
- group Id
- BG005
- spread
- 12.01
- value
- 60.3
- group Id
- BG006
- spread
- 12.24
- value
- 59.4
- group Id
- BG007
- spread
- 12.54
- value
- 58.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 10
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 36
- title
- Female
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 7
- group Id
- BG007
- value
- 34
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 10
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 55
- title
- White/Caucasian
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 6
- title
- Black/African-American
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Native Hawaiian/Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 5
- title
- Other
- title
- Race
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 67
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Not Reported
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Unknown
- title
- Ethnicity
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The safety population included all participants enrolled in the study who received at least 1 dose of epacadostat, pembrolizumab, or an applicable chemotherapy regimen.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle